United States · Platforms & data · Yahoo Finance

Stoke Therapeutics Inc (STOK) Q3 2026 Earnings Call Highlights: Strong Cash Runway and Phase 3 ...

Published by Yahoo Finance · United States 8 h ago

Stoke Therapeutics Inc (STOK) ended Q3 2026 with $358.8 million in cash to fund operations into early 2028, while advancing its Phase 3 EMPEROR study toward top-line data expected…

Read the full article on Yahoo Finance Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)

Also worth reading

MarketBeat

Sampo PLC (OTCMKTS:SAXPY) Stock Short Interest Declines 48.8%

The Motley Fool

Golden Dome Is a $185 Billion Program, but Anduril Is Private. Here Are the 3 Public Companies Building It.

Benzinga

Best Tech Stocks Right Now

Seeking Alpha

Talking Costco: Why a special dividend might not be the right play

MarketWatch

Grand Theft Callout: ‘GTA 6’ fans are missing work on the game’s release day because they ‘don’t want to wait’ anymore

TheStreet